INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – OGN

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged violations of the Securities Exchange Act of 1934, claiming misleading statements regarding the company's financial health and projections during the Class Period from November 3, 2022, to April 30, 2025 [1][4]. Group 1: Allegations and Financial Impact - The lawsuit alleges that Organon misrepresented the risk of loss of exclusivity and price erosion for its product Nexplanon, leading to inflated sales growth expectations that would not meet the projected $1 billion milestone by the end of fiscal year 2025 [4]. - It is claimed that Organon was not on track to achieve the required $1 billion in free cash flow to sustain its dividend, which was subsequently slashed by 90% from $1.16 per share annually to $0.08 per share annually [5]. - Following the announcement of the dividend cut, Organon's stock price fell by more than 27%, indicating a significant market reaction to the news [5]. Group 2: Legal Process and Representation - The lawsuit allows any investor who purchased Organon securities during the Class Period to seek appointment as lead plaintiff, representing the interests of the class [7]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, has a strong track record in prosecuting investor class actions and has recovered over $2.5 billion for investors in 2024 alone [8][9].